Inventiva to Present Abstracts at EASL Congress 2026

Inventiva, a clinical-stage biopharmaceutical company, will present two abstracts at the European Association for the Study of the Liver (EASL) Congress 2026, occurring from May 27-30 in Barcelona. The focus is on their drug candidate, lanifibranor, developed for metabolic dysfunction-associated steatohepatitis (MASH).

The first abstract, "Lanifibranor-induced improvements in histological parameters and cardiometabolic markers in MASH," discusses that these improvements are independent of weight change. It will be presented on May 29 by notable authors, including Mary E Rinella and Guillaume Wettstein.

The second abstract, "Ultrastructural assessment of liver sinusoidal endothelial cell capillarisation," studies the modulation of steatotic liver disease by lanifibranor. This presentation is scheduled for May 30, involving a team of authors led by Shivani Chotkoe.